Costanzi, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 215
EU - Europa 169
AS - Asia 85
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 478
Nazione #
US - Stati Uniti d'America 214
SE - Svezia 54
CN - Cina 38
DE - Germania 36
FR - Francia 26
SG - Singapore 21
PL - Polonia 12
IN - India 10
IE - Irlanda 9
ID - Indonesia 8
IT - Italia 8
UA - Ucraina 7
CI - Costa d'Avorio 6
FI - Finlandia 4
RU - Federazione Russa 4
BE - Belgio 3
GB - Regno Unito 3
TR - Turchia 3
EU - Europa 2
HK - Hong Kong 2
IR - Iran 2
NL - Olanda 2
AU - Australia 1
CA - Canada 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
Totale 478
Città #
Chandler 71
Singapore 17
Ashburn 15
New York 14
Kraków 12
Nanjing 10
Dublin 9
Jakarta 8
San Mateo 8
Ann Arbor 7
Marseille 7
Wilmington 7
Abidjan 6
Bremen 6
Jacksonville 6
Princeton 6
Boston 5
Dearborn 5
Beijing 3
Brussels 3
Cattolica 3
Fairfield 3
Helsinki 3
Izmir 3
Augusta 2
Changchun 2
Hong Kong 2
Los Angeles 2
Moscow 2
Rome 2
Seattle 2
Shenyang 2
Woodbridge 2
Zhengzhou 2
Chicago 1
Dongguan 1
Ergolding 1
Falkenstein 1
Guangzhou 1
Handan 1
Harbin 1
Houston 1
Kemerovo 1
Kish 1
Laojunmiao 1
Lawrence 1
Mountain View 1
Munich 1
Nanchang 1
Nanning 1
Oslo 1
Penrith 1
Redwood City 1
San Francisco 1
Stockholm 1
Tianjin 1
Toronto 1
Vientiane 1
Totale 281
Nome #
A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy. 138
Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura 69
Contrast-enhanced ultrasonography in chronic glomerulonephritides: correlation with histological parameters of disease activity 68
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: A randomized controlled trial 60
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies 55
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies 51
Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report 45
Totale 486
Categoria #
all - tutte 2.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.357


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202026 0 0 0 0 0 2 6 0 6 2 9 1
2020/202116 0 2 0 1 1 0 5 0 2 1 2 2
2021/202268 6 1 3 1 5 2 0 13 4 4 13 16
2022/2023181 26 22 12 34 7 26 15 13 19 0 5 2
2023/202462 3 14 1 7 0 8 6 1 0 4 9 9
2024/202536 1 1 11 6 11 6 0 0 0 0 0 0
Totale 486